| AiRuiKa (camrelizumab) / HLB Bio Group |
| Completed | 2 | 43 | RoW | Apatinib, SHR-1210 | Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd. | Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity | 10/19 | 01/20 | | |
NCT04294511: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma |
|
|
| Recruiting | 2 | 75 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Osteosarcoma | 03/21 | 09/23 | | |
NCT03711279: A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma |
|
|
| Terminated | 2 | 99 | RoW | SHR-1210 plus Apatinib, PD-1 antibody + Anti-angiogenesis, ADM plus IFO or IFO alone, chemotherapy | Jiangsu HengRui Medicine Co., Ltd. | Sarcoma | 06/21 | 06/21 | | |
NCT04606108: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 62 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Soft Tissue Sarcoma | 10/21 | 03/24 | | |
NCT04239443: Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer |
|
|
| Unknown status | 2 | 120 | RoW | PD-1 inhibitor, Camrelizumab, Apatinib | Hunan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd. | Advanced Non Small Cell Lung Cancer, Uterine Cancer, Soft Tissue Sarcoma | 03/22 | 03/22 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/23 | 06/24 | | |
|
NCT04044378: Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma |
|
|
| Withdrawn | 1/2 | 0 | RoW | Famitinib, Ifosfamide, Camrelizumab, camralizumab | Peking University People's Hospital, Peking University Shougang Hospital, Jiangsu HengRui Medicine Co., Ltd. | Effect of Drugs, Progression, Pediatric Cancer | 09/21 | 09/22 | | |
